# Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network.

**Tumor:** Cáncer gástrico/UGE
**Autores:** Tankel J
**Revista:** Ann Surg Oncol (2023)
**PMID:** 38142255 | **PMCID:** —
**DOI:** [10.1245/s10434-023-14779-4](https://doi.org/10.1245/s10434-023-14779-4)
**Fuente:** PubMed (abstract only)

## Relevancia
Cáncer gástrico/UGE tratado con quimioterapia perioperatoria (FLOT/MAGIC) o inmunoterapia: documenta downstaging ganglionar, valor pronóstico de ypN0 y rendimiento ganglionar tras NAC. Comparable al paradigma mamario: ypN0 tras quimioterapia neoadyuvante es marcador pronóstico fuerte y guía la linfadenectomía D2.

## Abstract
Retrospective cohort analysis from a regional upper gastrointestinal cancer network in Quebec, Canada. Overall, 236 of 420 patients met inclusion. Most cT3-4 (93.6%) and cN+ (61.0%). DCF and FLOT used in 127 and 109 respectively. R0 resection in 95.3%, pCR in 9.7% (DCF 12.6%/FLOT 6.4%). Median lymph node yield was 32, and 60.6% were ypN+. Overall survival similar between the groups. Neoadjuvant DCF and FLOT followed by transthoracic en bloc resection are both highly effective regimens for locally advanced esophageal adenocarcinoma.

## Acceso
Vía [DOI](https://doi.org/10.1245/s10434-023-14779-4) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.1245/s10434-023-14779-4*
